Perceptive Advisors LLC boosted its stake in Albireo Pharma, Inc. (NASDAQ:ALBO) by 56.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,320,000 shares of the biopharmaceutical company’s stock after buying an additional 475,000 shares during the period. Albireo Pharma makes up 1.1% of Perceptive Advisors LLC’s portfolio, making the stock its 22nd largest holding. Perceptive Advisors LLC owned 12.17% of Albireo Pharma worth $33,792,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently made changes to their positions in ALBO. Artal Group S.A. acquired a new position in Albireo Pharma in the 4th quarter valued at about $7,680,000. Sectoral Asset Management Inc grew its position in shares of Albireo Pharma by 53.6% during the 4th quarter. Sectoral Asset Management Inc now owns 242,803 shares of the biopharmaceutical company’s stock worth $6,216,000 after purchasing an additional 84,776 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Albireo Pharma during the 4th quarter worth approximately $216,000. Finally, Wells Fargo & Company MN grew its position in shares of Albireo Pharma by 282.1% during the 4th quarter. Wells Fargo & Company MN now owns 6,350 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 4,688 shares in the last quarter. Institutional investors and hedge funds own 29.43% of the company’s stock.
Albireo Pharma, Inc. (ALBO) opened at $34.35 on Monday. Albireo Pharma, Inc. has a 52-week low of $15.31 and a 52-week high of $39.87.
In related news, major shareholder Phase4 Partners Ltd sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $34.44, for a total transaction of $3,444,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Life Sciences Maste Perceptive purchased 275,000 shares of Albireo Pharma stock in a transaction that occurred on Thursday, January 25th. The shares were purchased at an average price of $33.00 per share, for a total transaction of $9,075,000.00. The disclosure for this purchase can be found here. Corporate insiders own 22.30% of the company’s stock.
Albireo Pharma Profile
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Want to see what other hedge funds are holding ALBO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albireo Pharma, Inc. (NASDAQ:ALBO).
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.